Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — 9M 2017 Earnings Presentation
28 slides from Pt Prodia Widyahusada Tbk's earnings presentation, October 2017
Slide 1: PT Prodia Widyahusada Tbk 9M2017 Results Update
PT Prodia Widyahusada Tbk 9M2017 Results Update October 2017
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: Contents
Contents Investment Highlights Growth Strategies 9M2017 Business Update Financial Highlights 3
Slide 4: Contents
Contents Investment Highlights Growth Strategies 9M2017 Business Update Financial Highlights 4
Slide 5: Contents: Investment Highlights
Contents Investment Highlights 1. The Forefront of a Significant Indonesian Healthcare Opportunity 2. Pioneer & Market Leader in the Indonesian Independent Clinical Lab Industry 3. Largest Nation-wide Lab Network, with the Largest National Reference Lab, and a Wholly-operated and scalable “Hub-and-S
Slide 6: The Forefront of a Significant Indonesian Healthcare Opportunity
Investment Highlights 1.1 The Forefront of a Significant Indonesian Healthcare Opportunity Revenue Growth (in IDR Billion) (In USD bn) A Population of 256 million – 4th Largest Worldwide (3) Rapidly expanding middle class 29.0 Strong GDP growth 26.5 27.6 25.4 2014 2015E 2016F 2017F Transform
Slide 7: Significant Growth Potential for Private Laboratories in Indonesia
Investment Highlights 1.2 Significant Growth Potential for Private Laboratories in Indonesia Indonesian Healthcare Market is Growing Private Laboratory Testing Market is Growing Faster (Market size by revenue; In USD bn) (Market size by revenue; In USD mn) 13A-15E CAGR 0.3% 817 28 29 27 27 25 26 706
Slide 8: Pioneer and Leader in Indonesian Independent Clinical Lab Industry
Investment Highlights 2.1 Pioneer and Leader in Indonesian Independent Clinical Lab Industry No.1 Independent Clinical Lab Chain Largest and Most Diversified Laboratory Network Market Share by Revenue of Key Players (2015) Number of Labs of 6 Key Players in Indonesia (2015) No. of Clinical Laborator
Slide 9: Pioneer in Clinical Laboratory Testing
2.2 Investment Highlights Pioneer in Clinical Laboratory Testing Received SMK3 accreditation and OHSAS 2015, along with the Award as "Diagnostic Services Company of Established professional the Year 2015" from Frost & Sullivan management team Opened the first green building used for laboratori
Slide 10: Largest Nationwide Network
Investment Highlights 3.1 Largest Nationwide Network I II VII Clinical Specialty POC Hospital Clinical Specialty POC Hospital Clinical Specialty POC Hospital Clinical Labs Labs Clinic Outlet Lab Labs Clinic Outlet Lab Labs Clinic Outlet Lab 132 and 1 PHC and 1 15 0 5 1 (Upgrade PHC : 10) 7 0 6 1 7 0
Slide 11: Scalable Hub and Spoke Model
Investment Highlights 3.2 Scalable Hub and Spoke Model Prodia Clinical Labs, Prodia National Centralized information with “Hub and spoke” model offers scalable Hospital and Other Clinics Reference Lab integrated IT platform that platform reducing turnaround time and refer tests to PNRL connect
Slide 12: Most Recognized Clinical Lab Brand in Indonesia
Investment Highlights 4 Most Recognized Clinical Lab Brand in Indonesia The only clinical lab in Indonesia accredited by College of American Pathologists (“CAP”(3)) Pioneer in Indonesian Laboratory Services Received 56% of the votes from a sample of Indonesian consumers in the 2015 Top-Brand Cen
Slide 13: Comprehensive Service Offering
Investment Highlights 5.1 Comprehensive Service Offering Targets Multiple Customer Segments 13
Slide 14: PRODIA Most Recognized Clinical Lab Brand
Investment Highlights 5.2 PRODIA Most Recognized Clinical Lab Brand Top Brand Indonesia Original Indonesia Best Brand Corporate Image Best E Mark Award Brand 2012 - 2016 Award (IBBA) Award (IMAC) 2016 2009 - 2017 2013 - 2016 2012 - 2017 Frost & Sullivan Award 2015 Service Quality Most Reputable Indo
Slide 15: Senior Leadership and Management Team
Investment Highlights 7 Senior Leadership and Management Team Experienced, Professional Management Team with a Track Record in Delivering Superior Growth and Innovation Diagnostic Services Company of the Year 2015 - Frost & Sullivan Top Brand Award 2017 15
Slide 16: Shareholder Composition
Investment Highlights Shareholder Composition PT Prodia Widyahusada Tbk Nationwide Outlet Network Across Indonesia PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 18% 25% 16
Slide 17: Contents
Contents Investment Highlights Growth Strategies 9M2017 Business Update Financial Highlights 17
Slide 18: 2017 Network Developments
2017 Network Developments Wilayah 1 : 21 Wilayah 2 : 14 Wilayah Wilayah 7:9 8 : 31 Wilayah 3 : 73 Wilayah Wilayah 5 : 46 6 : 35 Wilayah 4 : 44 1 Referral Lab Upgrade Clinical Hospital Clinical Lab & Next Gen Lab Specialty Clinic POC Outlets Lab to PHC Laboratories 5-7 (Jakarta) 2 20 8-10 3-5 1 18
Slide 19: Growth Strategy
Growth Strategy A Near-term 1 Expand our presence and grow our network of outlets in both existing and new markets in Indonesia 2 Upgrade existing clinical laboratories to provide wider range of tests and services and increase volume 3 Enhance internal operating efficiency 4 Focus on providing quali
Slide 20: Near Term Growth Plan
Near Term Growth Plan Prodia’s Network Expansion Plan by 2021 1 2 Expand Network of Outlets Upgrade Clinical Labs Upgrade up to 39 additional clinical labs to 4 regional referral labs(1) PHC Clinics(3) Up to 33 additional clinical labs over next five years 24 Clinical Lab Improvements Up to 20 new P
Slide 21: Leader in Next Generation Technology
Long-Term Strategy Leader in Next Generation Technology Immunology Laboratory Platforms Molecular Diagnostics (Flow Cytometry) Lab Innovation Diversified Clinical Diagnostics Platform + Scientific Talent Chromatography-Mass Advanced Pathology Lab Spectrometry The Concept of Precision Medicine Glob
Slide 22: Contents
Contents Investment Highlights Growth Strategies 9M2017 Business Update Financial Highlights 22
Slide 23: 9M 2017 Revenue
9M 2017 Revenue Revenue Growth (in IDR Billion) 1,359 1,198 1,081 1,042 986 946 2013 2014 2015 2016 9M 2016 9M 2017 Revenue increased by 10.2% driven by double-digit sales growths from External Referral and Corporate Client customers 23
Slide 24: Technology to Increase Customer Satisfaction
Technology to Increase Customer Satisfaction Launched e-Pay and e-Reg to increase distribution channel and provide easier way to register and payment system Payment can be made through ATM Transfer and Credit Card Customers can access their laboratory results through PRODIA apps and email 24
Slide 25: Contents
Contents Investment Highlights Growth Strategies 9M2017 Business Update Financial Highlights 25
Slide 26: 9M 2017 Gross Profit & Net Income (Unaudited)
Financial Highlights 9M 2017 Gross Profit & Net Income (Unaudited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) 602 99 57.8% 9.5% 545 29 57.6% 3.1% 9M 2016 9M 2017 9M 2016 9M 2017 Gross Profit Margin Net Income Margin Gross Profit increased by 20 bps as volume catches up and raw mater
Slide 27: 9M 2017 Cost Structure (Unaudited)
Financial Highlights 9M 2017 Cost Structure (Unaudited) Cost of Revenue (in IDR Billion) 565 511 Indirect Cost 454 90 440 384 82 401 72 475 74 Direct Cost 47 429 68 382 365 337 333 Total 42.0% 42.7% 41.6% 42.4% 42.2% 38.9% Cost of Revenues as % of Total Revenue 2013A 2014A 2015A 2016A 9M 2016A 9M 20
Slide 28: Thank you
Thank you
PT Prodia Widyahusada — 9M 2017 Earnings Presentation on 6ix